Ray Tancredi of Walgreens Give an Outlook on Oncology Drugs, Other Standouts in the Pipeline
Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been many oncology drug approvals. Over time, the number of approvals decreased each year.
Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been good number of oncology drug approvals. Over time, number of approvals each year have dropped down from 22, to 19 and so on.
As of 2023, there's only been two drugs approved, Tancredi sees that "there could be three or four drugs approved before the end of this year, maybe more." There's a number of products in the pipeline that could get approved this year.
"So when it's all said and done at the end of 2023, you know, we could be in double digits again, for as far as approvals are concerned," he added.
Rutgers Cancer Institute Reviews Guidelines for Managing Blood Cancers During Pregnancy
April 8th 2025About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer, accounting for 1 in 10,000 pregnancies. The most common pregnancy-related leukemias are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML).
Read More
CAR T-Cell Therapy Cuts Costs, Reduces Treatment in Mantle Cell Lymphoma
March 13th 2025In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
March 5th 2025Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer worldwide, marking a nearly 60% increase from 2020, according to BeiGene.
Read More
